Some patients with asthma outgrow their disease and reach clinical asthma remission (ClinR); these individuals experience no asthma symptoms even without using asthma medication. Patients in ClinR, however, might still have (asymptomatic) bronchial hyperresponsiveness (BHR) or impaired lung function [8] [9] [10] . BROEKEMA et al. [11] demonstrated that subjects in ClinR still had ongoing airway inflammation. In contrast, a smaller subset of asthma remission subjects may lack BHR and regain normal lung function, i.e. complete asthma remission (ComR) [10] .
We hypothesised that more SAD leads to decreased exhalation of PExA particles and that this SAD is still present in ClinR but absent in ComR subjects. Therefore, we compared exhaled PExA mass between ClinR and ComR subjects in relation to asthma patients and healthy controls. The second aim of this study was to investigate how PExA mass is associated with other measures of small and large airways function in these groups.
The study protocol was approved by the local ethical committee and all subjects gave informed consent (NL53173.042.15; Groningen, the Netherlands). The included subjects were divided over four groups: the first three groups were subjects with childhood-onset asthma that 1) persisted (PersA; subjects with wheezing and/or asthma attacks, asthma medication use, and a provocative concentration causing a 20% fall in forced expiratory volume in 1 s (PC 20 ) for methacholine of <8 mg·mL −1 with 120 s tidal breathing), or that 2) had gone into clinical asthma remission (ClinR; subjects without wheezing/asthma attacks, no use of asthma medication in the last 3 years, with a documented history of asthma according to Global Initiative for Asthma guidelines, a forced expiratory volume in 1 s (FEV 1 ) <80% predicted and/or PC 20 methacholine <8 mg·mL −1 ), or 3) into complete asthma remission (ComR; similar to ClinR, but with an FEV 1 ⩾80% pred, PC 20 methacholine ⩾8 mg·mL −1 and PC 20 AMP ⩾320 mg·mL −1 ); the fourth group was healthy controls (Ctrl; similar to ComR, but without any history of asthma or use of asthma medication).
@ERSpublications PExA mass can distinguish asthmatics from healthy individuals. Subjects with complete, but not clinical, asthma remission exhale more PExA mass compared to asthma. Higher PExA mass was associated with better function of both the small and large airways. All subjects were aged 40-65 years and were either never-or ex-smokers with a smoking history <10 pack-years. Subjects were extensively characterised with the following tests: spirometry, body plethysmography, IOS, F ENO , MBNW, provocation tests, blood tests, sputum induction and CT scans. PersA subjects were withdrawn from inhaled corticosteroids 6 weeks prior to the clinical characterisation.
PExA mass was collected using the PExA 2.0 device [5] . All subjects performed a similar breathing manoeuvre as described by BAKE et al. [6] . To account for potential bias effects of circadian rhythm, all PExA measurements were performed in the morning.
Parametric response mapping (PRM) is a voxel-wise image analysis technique that was implemented on the CT scans. PRM data were analysed according to the methods described in the literature [12, 13] . Clinical characteristics and PExA mass in the subject groups were compared using independent sample t-test for normally distributed data (including log2-transformed variables), Mann-Whitney U-tests for non-normally distributed data and Fisher's exact tests for categorical variables. Likewise, PExA mass was correlated with small and large airway parameters using either Pearson or Spearman tests. Last, a stepwise multivariate regression analysis was performed to assess independent associations with PExA mass.
Clinical characteristics of the subject groups are presented in table 1. ComR subjects were significantly younger than PersA subjects ( p=0.027). The FEV 1 was significantly higher in Ctrl and ComR compared to PersA subjects, and higher in ComR compared to ClinR subjects.
PExA mass was significantly lower in PersA compared to ComR and Ctrl subjects ( p=0.028 and p=0.003, respectively) ( figure 1 ). In addition, PExA mass was significantly lower in ClinR compared to Ctrl subjects ( p=0.018). Comparison of particle size distribution per group did not yield additional information. This is the first study investigating exhaled particles in asthma remission subjects, showing a similar PExA mass in ComR compared to healthy controls and a decrease in PExA mass in ClinR compared to healthy controls, even though these individuals experience no wheeze or asthma attacks. Our findings are in concordance with the previously stated hypothesis that more SAD leads to decreased exhalation of particles. The fact that ClinR subjects exhale fewer particles suggests that these subjects still have ongoing SAD similar to persistent asthmatics. In contrast, ComR subjects exhale similar amounts of particles compared to healthy controls, possibly due to outgrown SAD. Next, we assessed the correlations between PExA mass and known small and large airway parameters. Results of these bivariate correlations are presented in table 1. Increased PExA mass was associated with less severe BHR and parameters of both large airway function (higher FEV 1 % pred and higher ratio of FEV 1 to forced vital capacity (FVC)) and small airway function (higher forced expiratory flow at 25-75% of the pulmonary volume % pred, less hyperinflation as reflected by lower residual volume % pred, lower IOS resistance at 5 Hz minus resistance at 20 Hz (R 5 −R 20 ) and decreased MBNW conductive ventilation heterogeneity multiplied by tidal volume (S cond ×V T )). No correlation with PExA mass and PRM-defined (functional) small airways disease was observed. Finally, a stepwise multiple regression analysis was performed, including all variables significantly associated with PExA mass in the bivariate analysis (table 1) . This analysis showed that MBNW S cond ×V T was independently associated with PExA mass.
SOARES et al. [4] found a correlation between mean number of particles per exhalation and FEV 1 /FVC ratio (R=0.246, p=0.021), and between surfactant A PExA concentration and R 5 −R 20 (R=0.257, p<0.05). In accordance with these findings of SOARES et al. [4] , we show that increased PExA mass is associated with better function of both the large and the small airways.
In conclusion, PExA mass can distinguish asthmatics from healthy individuals. In addition, we show that subjects with complete, but not clinical, asthma remission exhale more PExA mass compared to asthma subjects. Our findings are in concordance with previous studies showing that decreased PExA mass is associated with more severe obstructive pulmonary disease [7, 14] . These results reinforce the theory that clinical asthma remission subjects still have ongoing SAD and that subjects in complete asthma remission have completely outgrown their disease [10] . Our observations demonstrate that higher PExA mass is not only related to better large airway function, but also independently associated with SAD as reflected by S cond . This indicates that PExA mass could potentially be used as a tool to assess SAD. Future research should focus on exploring the composition of exhaled particles to gain more insight into the
